SG11201407043PA - Method for the preparation of triazole compounds - Google Patents
Method for the preparation of triazole compoundsInfo
- Publication number
- SG11201407043PA SG11201407043PA SG11201407043PA SG11201407043PA SG11201407043PA SG 11201407043P A SG11201407043P A SG 11201407043PA SG 11201407043P A SG11201407043P A SG 11201407043PA SG 11201407043P A SG11201407043P A SG 11201407043PA SG 11201407043P A SG11201407043P A SG 11201407043PA
- Authority
- SG
- Singapore
- Prior art keywords
- triazol
- morpholin
- keto
- enol
- internationales
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- -1 triazole compounds Chemical class 0.000 title abstract 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 3
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 abstract 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000002085 enols Chemical group 0.000 abstract 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167152 | 2012-05-08 | ||
| PCT/EP2013/059418 WO2013167552A1 (de) | 2012-05-08 | 2013-05-06 | Verfahren zur herstellung von triazol-verbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407043PA true SG11201407043PA (en) | 2014-12-30 |
Family
ID=48325714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201609319YA SG10201609319YA (en) | 2012-05-08 | 2013-05-06 | Method for the preparation of triazole compounds |
| SG11201407043PA SG11201407043PA (en) | 2012-05-08 | 2013-05-06 | Method for the preparation of triazole compounds |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201609319YA SG10201609319YA (en) | 2012-05-08 | 2013-05-06 | Method for the preparation of triazole compounds |
Country Status (35)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2639716B2 (ja) | 1988-12-14 | 1997-08-13 | 横浜ゴム株式会社 | タイヤ成形装置に於けるグリーンタイヤの搬送装置 |
| US10703742B2 (en) * | 2016-05-03 | 2020-07-07 | Bayer Pharma Aktiengesellschaft | Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives |
| CN108084099B (zh) * | 2017-12-20 | 2019-01-29 | 天驰药业有限公司 | 一种1,2,3-三氮唑化合物的合成方法 |
| US10702525B1 (en) | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
| EP3888684A1 (en) | 2020-03-31 | 2021-10-06 | Bayer Animal Health GmbH | Composition having improved voluntary acceptance |
| JP7710897B2 (ja) * | 2021-06-01 | 2025-07-22 | 三菱ガス化学ネクスト株式会社 | １－アルキル－５－ヒドロキシピラゾールの製造方法 |
| CN114264752B (zh) * | 2021-12-29 | 2023-08-15 | 北京金城泰尔制药有限公司 | 溴乙酸甲酯的检测方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4572910A (en) * | 1983-03-03 | 1986-02-25 | Riker Laboratories, Inc. | Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
| DK135184A (da) | 1983-03-03 | 1984-10-10 | Riker Laboratories Inc | Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner |
| US4752910A (en) | 1984-10-30 | 1988-06-21 | Prime Computer, Inc. | Method and apparatus for continuous after-imaging |
| UY27813A1 (es) * | 2002-05-31 | 2003-12-31 | Smithkline Beecham Corp | Inhibidores de la peptido-desformilasa |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| CN1871208A (zh) * | 2003-10-30 | 2006-11-29 | 默克公司 | 作为大麻素受体调节剂的芳烷基胺 |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| DE102008020113A1 (de) | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| WO2006114706A1 (en) | 2005-04-26 | 2006-11-02 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| EP1885713A1 (en) | 2005-05-18 | 2008-02-13 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| DE102006050516A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| DE102010041236A1 (de) * | 2010-09-23 | 2012-03-29 | Osram Ag | Optoelektronisches Halbleiterbauelement |
| DE102010044131A1 (de) * | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
-
2013
- 2013-05-06 US US14/399,929 patent/US10301289B2/en active Active
- 2013-05-06 WO PCT/EP2013/059418 patent/WO2013167552A1/de active Application Filing
- 2013-05-06 SG SG10201609319YA patent/SG10201609319YA/en unknown
- 2013-05-06 CA CA2872726A patent/CA2872726C/en active Active
- 2013-05-06 AP AP2014008089A patent/AP2014008089A0/xx unknown
- 2013-05-06 MY MYPI2014703274A patent/MY184577A/en unknown
- 2013-05-06 LT LTEP13720943.3T patent/LT2847183T/lt unknown
- 2013-05-06 RS RS20170869A patent/RS56255B1/sr unknown
- 2013-05-06 PL PL13720943T patent/PL2847183T3/pl unknown
- 2013-05-06 EP EP13720943.3A patent/EP2847183B1/de active Active
- 2013-05-06 PT PT137209433T patent/PT2847183T/pt unknown
- 2013-05-06 AU AU2013258107A patent/AU2013258107B2/en active Active
- 2013-05-06 ES ES13720943.3T patent/ES2641205T3/es active Active
- 2013-05-06 PE PE2014001942A patent/PE20142453A1/es active IP Right Grant
- 2013-05-06 MX MX2014013448A patent/MX350519B/es active IP Right Grant
- 2013-05-06 UA UAA201413001A patent/UA116349C2/uk unknown
- 2013-05-06 HU HUE13720943A patent/HUE034430T2/en unknown
- 2013-05-06 EA EA201492032A patent/EA027804B1/ru not_active IP Right Cessation
- 2013-05-06 SG SG11201407043PA patent/SG11201407043PA/en unknown
- 2013-05-06 KR KR1020147033989A patent/KR102086389B1/ko active Active
- 2013-05-06 NZ NZ701661A patent/NZ701661A/en unknown
- 2013-05-06 JP JP2015510775A patent/JP6149104B2/ja active Active
- 2013-05-06 BR BR112014027564-5A patent/BR112014027564B1/pt active IP Right Grant
- 2013-05-06 CN CN201380036548.5A patent/CN104411704B/zh active Active
- 2013-05-06 SI SI201330768T patent/SI2847183T1/sl unknown
- 2013-05-06 HR HRP20171321TT patent/HRP20171321T1/hr unknown
- 2013-05-06 DK DK13720943.3T patent/DK2847183T3/en active
-
2014
- 2014-11-02 IL IL235441A patent/IL235441A/en active IP Right Grant
- 2014-11-04 CO CO14243310A patent/CO7121324A2/es unknown
- 2014-11-06 CU CU2014000128A patent/CU20140128A7/es unknown
- 2014-11-06 PH PH12014502482A patent/PH12014502482A1/en unknown
- 2014-11-06 CL CL2014003003A patent/CL2014003003A1/es unknown
- 2014-11-07 DO DO2014000254A patent/DOP2014000254A/es unknown
- 2014-11-07 TN TN2014000469A patent/TN2014000469A1/fr unknown
- 2014-11-07 CR CR20140514A patent/CR20140514A/es unknown
- 2014-11-21 ZA ZA2014/08571A patent/ZA201408571B/en unknown
-
2016
- 2016-05-13 CL CL2016001165A patent/CL2016001165A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407043PA (en) | Method for the preparation of triazole compounds | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201804672QA (en) | Systems and methods for production of low oxygen content silicon | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201806855WA (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |